1. Definition and etiology (TB as most common in India)
2. Pathophysiology and hemodynamic features (ventricular interdependence, square root sign, Kussmaul's - all high-yield exam topics)
3. Comparison with cardiac tamponade (classic examiner's table)
4. Preoperative assessment and optimization
5. Anaesthetic goals - the "4F rule" (Fast, Full, Strong, Forward)
6. Monitoring (mandatory invasive monitoring, TEE role)
7. Premedication
8. Induction of anaesthesia - drug selection, Ketamine vs Etomidate as agents of choice, AVOID propofol/thiopentone
9. Airway and ventilation strategy (low TV, high RR, minimal PEEP)
10. Maintenance
11. Surgical approach and intraoperative hazards (especially acute RV dilation post-stripping)
12. Post-bypass/post-pericardiectomy management
13. ICU care including epidural analgesia
14. Special situations (TB-CP, radiation CP, effusive-constrictive)
15. Complications and prognosis

• CO = HR × fixed SV, therefore HR is the only modulator
• Ketamine is the induction agent of choice (sympathomimetic)
• TEE is mandatory intraoperatively
• Acute RV dilation immediately after pericardial stripping is the most feared intraoperative complication
• Coagulopathy/DIC occurs due to fibrinolytic activator release from raw myocardium
• Operative mortality 5-10% (up to 21% for radiation-induced)

PATHOPHYSIOLOGY OF AORTIC CROSS-CLAMPING AND UNCLAMPING, AND RENAL PROTECTION MEASURES

INTRODUCTION

PART 1: PATHOPHYSIOLOGY OF AORTIC CROSS-CLAMPING

A. Levels of Aortic Cross-Clamping

1. Supraceliac (above the coeliac axis)
2. Suprarenal (between the coeliac axis and renal arteries)
3. Infrarenal (below both renal arteries - most common, best tolerated)

B. Haemodynamic Response to Cross-Clamping

1. Afterload (SVR)

• The most dramatic and consistent effect of AoX is a sudden increase in systemic vascular resistance (SVR) and mean arterial pressure (MAP) due to abrupt impedance to aortic flow.
• Magnitude depends on clamp level:

2. Preload - Blood Volume Redistribution (KEY CONCEPT)

• AoX causes blood volume redistribution proximal to the clamp by passive venous recoil from vessels distal to occlusion.
• The net effect on preload depends on clamp level and splanchnic capacitance:

• Splanchnic circulation is occluded - it cannot absorb the redistributed blood volume
• Decrease in splanchnic arterial flow → decrease in venous capacitance by elastic recoil
• Result: Net increase in venous return, CVP, PCWP, and cardiac preload
• LV end-diastolic volume increases markedly

• Splanchnic circulation remains intact (above the clamp)
• Redistributed blood volume shifts into the compliant splanchnic vascular bed
• This dampens the expected preload increase
• Preload changes are variable and inconsistent

3. Cardiac Output

• With supraceliac/suprarenal AoX: The combination of increased preload AND afterload dramatically increases myocardial work
  • Normal hearts: coronary vasodilation compensates, CO may be maintained or increase
  • Diseased hearts (reduced EF, significant CAD): coronary vasculature already maximally dilated - cannot compensate - myocardial ischaemia and cardiac failure result
  • New LV wall motion abnormalities in 92% of patients with supraceliac clamp
• With infrarenal AoX: CO decreases 9-33%; usually clinically manageable

4. Heart Rate

• AoX itself has little to no direct effect on heart rate
• Baroreceptor activation from increased aortic pressure may reflexly reduce HR, contractility, and vascular tone

5. Myocardial Effects (Afterload Mismatch)

• Increased afterload → increased LV wall stress
• Impaired LV (common in the elderly) cannot handle the acute volume and pressure overload
• Afterload mismatch: increased afterload → increased LV end-systolic volume → reduced stroke volume
• This leads to progressive LV distension, subendocardial ischaemia, pulmonary oedema

6. Metabolic Effects

• Thoracic AoX decreases total body O2 consumption by ~50% (below-clamp ischaemia)
• O2 consumption ABOVE the clamp paradoxically also decreases (unclear mechanism)
• Mixed venous O2 saturation increases above clamp (O2 consumption decreases > CO falls)
• Distal to thoracic AoX: arterial BP, blood flow, and O2 consumption fall by 78-88%, 79-88%, and 62% respectively

C. Anaesthetic Management During Cross-Clamping

1. Control of proximal hypertension:
   • Vasodilators: Sodium nitroprusside (SNP) - bolus or infusion; nitroglycerin (GTN); nicardipine
   • Esmolol: Reduce HR to 60-65 bpm target to limit myocardial O2 demand
   • Deepening volatile anaesthesia
   • Thoracic epidural local anaesthetic (L.A. epidural at T6 level - provides sympathetic blockade, reduces SVR)
   • Important caution: Aggressive SVR reduction above the clamp can further compromise blood flow DISTAL to the clamp (visceral, spinal cord, renal ischaemia) - a critical balance must be maintained
2. Monitor for ischaemia:
   • Continuous ECG (5-lead, ST analysis)
   • TEE - LV wall motion abnormalities, LVEDA/LVESA, EF
   • PAC if required in complex cases (PCWP)

PART 2: PATHOPHYSIOLOGY OF AORTIC UNCLAMPING

A. The "Declamping Syndrome"

B. Mechanisms of Hypotension on Unclamping

1. Acute Fall in SVR (Central to the Response)

• Release of the clamp suddenly restores blood flow into the ischaemic, vasodilated distal vascular beds
• The ischaemic tissues distal to the clamp undergo reactive hyperaemia - maximal vasodilation from accumulated metabolic vasodilatory mediators:
  • CO2, lactic acid, adenosine, prostaglandins, oxygen free radicals, hypoxanthine
• This dramatically reduces SVR → acute fall in MAP

2. Reduced Preload (Pooling of Blood)

• Sudden redistribution of blood volume INTO the previously ischaemic distal beds ("third spacing")
• Venous pooling in dilated distal capacitance vessels
• Effective circulating volume decreases
• CVP and PCWP fall → reduced LV filling → reduced CO and BP

3. Metabolic Reperfusion Effects - "Washout Phenomenon"

• Release of accumulated ischaemic metabolites from distal tissues into the systemic circulation:
  • Lactic acidosis (metabolic acidosis)
  • Hyperkalaemia
  • Myocardial depressant factors (cytokines, TNF-α, interleukins)
  • Oxygen free radicals (ischaemia-reperfusion injury)
  • Adenosine (vasodilatory)
  • CO2 surge
• These directly depress myocardial contractility and further reduce BP

4. Ischaemia-Reperfusion (I/R) Injury

• Reperfusion after ischaemia paradoxically generates more injury than ischaemia alone
• Mechanisms: xanthine oxidase-mediated free radical generation, neutrophil activation, endothelial dysfunction, complement activation
• Affects: myocardium, kidneys, spinal cord, gut (mesenteric ischaemia)

5. Proximal Hypertension "Rebound"

• After unclamping, the proximal vasodilator therapy (SNP/GTN) that was reducing afterload now acts without the increased SVR of clamping → profound hypotension

C. Factors Affecting Severity of Declamping Hypotension

D. Haemodynamic Changes on Unclamping (Summary Table)

E. Anaesthetic Management During Unclamping

1. Communicate with surgeon - ensure adequate preparation time
2. IV fluid loading - administer 500-1000 mL crystalloid/colloid before release to expand intravascular volume
   • Infrarenal: moderate pre-load (~500 mL)
   • Supraceliac/suprarenal: more aggressive volume loading required
3. Wean and stop vasodilators (SNP/GTN) - discontinue before unclamping to avoid additive hypotension
4. Reduce volatile anaesthetic depth - lighten anaesthesia to improve sympathetic tone
5. Vasopressor/inotrope infusions ready: Noradrenaline, phenylephrine, dopamine, adrenaline
6. Sodium bicarbonate (NaHCO3 1-2 mEq/kg IV) - to buffer anticipated metabolic acidosis
7. Calcium gluconate/chloride - to manage hyperkalaemia and support myocardial contractility
8. Do NOT maintain elevated CVP/PCWP during clamp period (leads to significant overtransfusion)

• Request gradual, slow clamp release by surgeon (not sudden)
• If severe hypotension: reapply clamp or digital compression by surgeon while resuscitation continues
• Once haemodynamics stabilise, gradually remove clamp fully
• Treat metabolic acidosis (NaHCO3), hyperkalaemia (calcium, hyperventilation, bicarbonate)
• Monitor for arrhythmias (VF, VT) from hyperkalaemia

PART 3: RENAL PROTECTION DURING AORTIC CROSS-CLAMPING

A. Magnitude of the Problem

• Acute renal failure (ARF) occurs in ~3% of elective infrarenal aortic reconstructions
• Mortality from postoperative ARF exceeds 40%
• The incidence has remained largely unchanged despite improvements in perioperative care

B. Pathophysiology of Renal Ischaemia During AoX

C. Renal Protection Measures

1. MAINTAIN ADEQUATE PERFUSION PRESSURE AND VOLUME

• Most fundamental measure
• Goal: MAP ≥ 70-80 mmHg above the clamp
• Avoid hypovolaemia and hypotension at all times
• IV fluid optimisation before, during, and after clamping
• Volume loading before unclamping to prevent hypotensive reperfusion injury

2. MANNITOL (Most Widely Used)

• Dose: 0.25-0.5 g/kg IV bolus (12.5 g/70 kg is standard dose) before aortic cross-clamping
• Mechanisms of renal protection:
  • Induces osmotic diuresis - flushes tubular debris, reduces tubular cast formation
  • Improves renal cortical blood flow during infrarenal AoX
  • Reduces ischaemia-induced renal vascular endothelial cell oedema and vascular congestion
  • Free radical scavenger - reduces ischaemia-reperfusion injury
  • Decreases renin secretion
  • Increases renal prostaglandin synthesis (vasodilatory)
  • Reduces intracellular oedema of renal tubular cells
• Timing: Give before cross-clamping for optimal effect
• Caution: In patients with poor cardiac function - osmotic expansion of intravascular volume may precipitate pulmonary oedema

3. LOOP DIURETICS (Furosemide)

• Increase urine flow and decrease tubular oxygen demand
• May protect against tubular obstruction by casts
• Used particularly for patients with pre-existing renal insufficiency
• Requires increased electrolyte monitoring (hypokalaemia, hypomagnesaemia) and volume replacement
• Risk: Overuse → hypovolaemia → worsened renal perfusion (paradoxical harm)

4. DOPAMINE (Low-dose / "Renal dose")

• Dose: 1-3 mcg/kg/min
• Proposed mechanism: Dopamine-1 (DA1) receptor stimulation → renal afferent and efferent arteriolar vasodilation → increased RBF and GFR → increased urine output
• Reduces renal tubular sodium reabsorption (tubular DA1 receptors) → reduces tubular O2 consumption
• Clinical evidence: Highly controversial; no convincing evidence that low-dose dopamine improves postoperative renal outcomes
• Risks of dopamine in this context:
  • Positive inotropic and chronotropic effects → tachycardia → increased myocardial O2 consumption in patients with limited coronary reserve
  • Splanchnic vasoconstriction at higher doses
• Current status: Routine use is not evidence-based; commonly used as adjunct in suprarenal clamping

5. FENOLDOPAM MESYLATE

• A selective Dopamine-1 (DA1) receptor agonist - preferentially dilates renal and splanchnic vascular beds WITHOUT the adrenergic effects of dopamine
• Has shown promise as a renoprotective drug in some studies
• Avoids the tachycardia/arrhythmia side effects of dopamine
• Current evidence: Role not definitively established; used in suprarenal AoX cases
• May cause systemic hypotension (vasodilation)

6. N-ACETYLCYSTEINE (NAC)

• Free radical scavenger, antioxidant
• Theoretical benefit via reduction of ischaemia-reperfusion injury
• Some benefit in contrast nephropathy; limited data for AoX renal protection

7. AVOID NEPHROTOXINS

• Stop NSAIDs preoperatively
• Stop ACE inhibitors/ARBs preoperatively (reduce intrarenal autoregulation)
• Avoid aminoglycosides, contrast agents perioperatively
• Minimise vasopressor overuse (vasoconstriction worsens renal ischaemia)

8. MINIMISE CROSS-CLAMP TIME

• The duration of aortic cross-clamping is one of the strongest predictors of renal injury
• Shorter clamp time → less ischaemia → less ATN
• Surgeon proficiency and preparation of anastomosis before clamping is essential

9. MAINTAIN HAEMATOCRIT AND OXYGEN DELIVERY

• Anaemia reduces O2 delivery to ischaemic kidneys
• Target Hct ≥ 25-30% (especially before clamping)
• Avoid fluid overload vs. hypovolaemia balance

10. REGIONAL COOLING OF KIDNEYS (Surgical)

• Used for suprarenal/supraceliac procedures
• Ice slush instilled around the kidneys via retroperitoneal dissection
• Reduces renal metabolic rate and ischaemic injury

11. COLD RENAL PERFUSION (Surgical)

• For very long suprarenal clamp times
• Cold (4°C) crystalloid or Ringer's lactate solution perfused directly into renal arteries via cannulae
• Reduces renal core temperature → reduces metabolic demand

12. MINIMISE DISTAL AORTIC ISCHAEMIA - ADJUNCTS

• Left heart bypass (LHB) or partial CPB: For thoracoabdominal surgery - maintains distal aortic perfusion including renal arteries during proximal clamp
• Reduces clamp-to-organ ischaemia time
• Particularly important for Type I/II TAAA (Crawford classification)

13. EPIDURAL ANAESTHESIA (COMBINED TECHNIQUE)

• Renal sympathetic block (T6 epidural) theoretically reduces renal vasoconstriction
• However, studies show it does NOT prevent the severe impairment of renal perfusion and function during/after infrarenal AoX
• Primary benefit is postoperative analgesia and reduced systemic anaesthetic requirements

D. Summary Table: Renal Protection Strategies

KEY EXAM SUMMARY POINTS

1. Supraceliac AoX = most severe haemodynamic response (↑MAP 54%, EF falls 38%, 92% RWMA)
2. Infrarenal AoX = most common, best tolerated but still causes 38% fall in RBF despite systemic haemodynamics being near-normal
3. Blood volume redistribution distal-to-proximal is the key mechanism explaining preload changes
4. Unclamping: SVR ↓ + venous pooling + metabolite washout (acidosis, ↑K+, myocardial depressants) = hypotension
5. Prepare before unclamping: fluid load, wean vasodilators, reduce volatile, vasopressors ready, NaHCO3, slow release
6. Renal protection: Mannitol is the cornerstone (free radical scavenger + osmotic diuresis + cortical flow); minimise clamp time; maintain perfusion pressure; avoid nephrotoxins
7. Urine output does NOT predict renal protection - measure of flow not function
8. Strongest predictor of post-op renal failure: pre-existing renal insufficiency
9. ARF after aortic surgery: 3% incidence but >40% mortality - prevention is paramount
10. Epidural anaesthesia does NOT prevent renal vasoconstriction from infrarenal AoX

REFERENCES

• Barash, Cullen, Stoelting's Clinical Anaesthesia, 9th Edition - Chapter 40 (Anaesthesia for Vascular Surgery): Pathophysiology of Aortic Occlusion and Reperfusion
• Miller's Anaesthesia, 10th Edition - Chapter 52: Renal Function and Protection; Therapeutic Strategies for Thoracoabdominal Aortic Surgery
• Morgan & Mikhail's Clinical Anaesthesiology, 7th Edition - Chapter on Vascular Anaesthesia
• Gelman S. The pathophysiology of aortic cross-clamping and unclamping. Anaesthesiology. 1995;82(4):1026-1060 (Classic Reference - Examiner's Favourite)